These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36309414)

  • 21. Testosterone therapy in prostate cancer: is it still a controversy?
    Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
    Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canadian Society for the Study of the Aging Male: response to health Canada's position paper on testosterone treatment.
    Bain J; Brock G; Kuzmarov I; For The International Consulting Group
    J Sex Med; 2007 May; 4(3):558-566. PubMed ID: 17498097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
    J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer.
    Catarinicchia SP; Crawford ED
    Nat Rev Urol; 2016 Sep; 13(9):497-8. PubMed ID: 27431338
    [No Abstract]   [Full Text] [Related]  

  • 28. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
    J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
    Meza J; Weaver K; Martin S
    Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
    [No Abstract]   [Full Text] [Related]  

  • 31. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
    Jensen CF; Fode M; Østergren P; Sønksen J
    Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testosterone replacement therapy for late-onset hypogonadism.
    Cunningham GR
    Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testosterone Therapy in Men With Prostate Cancer.
    Kaplan AL; Hu JC; Morgentaler A; Mulhall JP; Schulman CC; Montorsi F
    Eur Urol; 2016 May; 69(5):894-903. PubMed ID: 26719015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
    Khera M; Adaikan G; Buvat J; Carrier S; El-Meliegy A; Hatzimouratidis K; McCullough A; Morgentaler A; Torres LO; Salonia A
    J Sex Med; 2016 Dec; 13(12):1787-1804. PubMed ID: 27914560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
    Miner M; Canty DJ; Shabsigh R
    Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Words of Wisdom. Re: incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Butler P; Scovell JM; Ramasamy R; Lipshultz LI
    Eur Urol; 2015 Jun; 67(6):1186-7. PubMed ID: 25944034
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of testosterone replacement therapy in patients with prostate cancer.
    Dorff TB; Vogelzang NJ
    Curr Urol Rep; 2011 Jun; 12(3):223-8. PubMed ID: 21365235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
    Johansen KL
    Semin Dial; 2004; 17(3):202-8. PubMed ID: 15144546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.